Defunct Company
Total Trials
7
As Lead Sponsor
0
As Collaborator
Total Enrollment
294
NCT00979173
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
Phase: Phase 1
Role: Collaborator
Start: Nov 30, 2009
Completion: Jun 30, 2012
NCT01411267
AC220 for Children With Relapsed/Refractory ALL or AML
Start: Sep 1, 2011
Completion: Sep 12, 2013
NCT01390337
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Start: Oct 31, 2011
Completion: Feb 28, 2015
NCT01468467
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Start: Apr 30, 2012
Completion: Mar 31, 2015
NCT01565668
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase 2
NCT03845881
Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty
Phase: Early Phase 1
Start: Apr 10, 2019
Completion: Jul 28, 2020
NCT04681092
Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study
Phase: Phase 1/2
Start: Apr 6, 2021
Completion: Mar 10, 2022